Top Page
Advanced Human Imaging
(AHI)
Advanced Human Imaging (AHI) vs. iShares MSCI Australia ETF (EWA)
Advanced Human Imaging Business Overview & Revenue Model
Advanced Human Imaging Financial Statement Overview
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Advanced Human Imaging Technical Analysis
Advanced Human Imaging Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― |
Advanced Human Imaging Corporate Events
Advanced Health Intelligence Ltd has secured up to AUD $5.5 million in funding from Oakley Capital Partners, which will aid in its reinstatement to trading on the ASX and support its growth initiatives. The company is also pursuing additional funding to ensure a robust 12-month cash position and expects to receive up to AUD $3 million in non-dilutive capital through R&D grants. These financial strategies are part of AHI’s broader plan to enhance its balance sheet resilience and continue its commercial and strategic growth initiatives, despite its securities being suspended from trading.
Advanced Health Intelligence Ltd has announced a proposed issue of securities, including 27.5 million options and 20 million ordinary fully paid shares, with an expected issue date of October 8, 2025. This move is part of the company’s strategy to raise capital, potentially enhancing its market position and providing additional resources for growth and development, which could have significant implications for stakeholders and the company’s future operations.
Advanced Health Intelligence Ltd has announced a proposed issue of securities, with plans to issue up to 82,500,000 new securities, including options and ordinary shares. This move is aimed at raising capital to support the company’s operations and growth strategies. The issuance is set for October 8, 2025, and is expected to enhance the company’s market position by providing additional financial resources, potentially impacting stakeholders positively by bolstering the company’s capacity for innovation and expansion in the health technology sector.
Advanced Health Intelligence Ltd has announced a proposed issue of 31,625,000 ordinary fully paid securities, with a planned issue date of April 1, 2027. This move is part of the company’s strategy to enhance its market positioning and operational capabilities, potentially impacting its stakeholders by increasing its financial resources and investment capacity.
Advanced Health Intelligence Ltd. has secured a funding commitment of up to AUD$5.5 million from Oakley Capital Partners to support its reinstatement to trading on the ASX and future growth initiatives. The funding will be structured through a private placement and convertible note facility, forming a crucial part of AHI’s broader capital strategy. Additionally, AHI is pursuing further funding opportunities, including a potential USD$6 million from strategic investors and up to AUD$3 million in non-dilutive R&D grants, to ensure a robust cash position and support its global growth strategy. The company has also implemented cost-reduction measures to enhance capital efficiency and is actively working towards meeting ASX compliance requirements for reinstatement.
Advanced Health Intelligence Ltd has had a commercially active quarter, marked by significant international expansion and technological advancements. The company launched the HIQOR platform in collaboration with Bearn LLC, secured its first insurance deployment with Unisure, and was listed on the Microsoft Azure Marketplace. AHI also received a U.S. patent for its smartphone-based disease risk assessment technology, reinforcing its leadership in mobile digital health. These developments position AHI for global scaling, with substantial funding initiatives and strategic partnerships supporting its growth and operational capacity.
Advanced Health Intelligence Ltd has announced its ongoing efforts to restore compliance with the ASX and NASDAQ exchanges following the delisting of its American Depositary Shares from NASDAQ due to shareholder equity deficiencies. The company is focused on reinstating its securities on the ASX by completing outstanding financial audits and governance submissions, which are prerequisites for any potential relisting on NASDAQ. AHI is actively seeking funding to meet these requirements and aims to demonstrate financial stability and governance readiness to regain its market position. The company has set a deadline to release its FY2024 Annual Report by 30 September 2025 to avoid removal from the ASX official list.
Advanced Health Intelligence Ltd has been granted a 31-day extension by AusIndustry to finalize its FY2024 R&D reimbursement submission, allowing the company to include international R&D expenditures in its claim. This extension is crucial for AHI as it anticipates receiving approximately AUD $1.1 million, which will support its operational execution during a critical phase of commercial expansion. The company’s consistent R&D reimbursements since 2017 highlight its commitment to innovation in the med-tech sector, while its expanding patent portfolio and global R&D activities reinforce its position as a leader in digital health. Additionally, AHI is pursuing an R&D Advance Facility for AUD $750,000, which, combined with the expected reimbursement, will strengthen its cash flow position with up to AUD $1,850,000 in non-dilutive capital.